Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

Inclusion Criteria: * Written informed consent * Male or female ≥18 years of age * Meet European Society of Cardiology (ESC) criteria for diagnosis of HF1 * Elevated natriuretic peptide (BNP\> 100 pg/mL or NTproBNP \>300 pg/mL) * Signs and symptoms of HF * Echocardiographic structural or functional abnormality according to ESC guidelines * Have received IV diuretic for treatment of HF within preceding 24 hours * Be less than 96 hours after admission to hospital * Requiring IV diuretics for a minimum of 24 hours after screening * Have an echocardiogram or other assessment of cardiac structure and function within preceding 12 months or at screening * Have a home environment that allows the patient to be able to mobilise within their residence and be able to pass urine into their toilet (unless catheterised) * Able to operate (or has a caregiver who can operate) SQIN-Infusor (as assessed by training on a dummy device at screening) Exclusion Criteria: * Unable to consent due to significant cognitive impairment or lack of capacity * Unable to operate SQIN-Infusor (or no caregiver who is able to operate the device) * Geographical reasons preventing follow-up visits * Pregnancy or breast-feeding * Requiring treatment with IV furosemide \>250 mg furosemide per day in the opinion of the treating physician * Left sided valve disease with planned surgery or percutaneous intervention * Type 1 myocardial infarction during index hospitalisation (participants with type 2 myocardia…